文献速递胸部肿瘤

深度学习模型预测晚期非小细胞肺癌免疫治疗反应

Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项多中心队列研究开发并独立验证了基于苏木精-伊红染色全切片图像的深度学习反应分层模型,用于预测晚期非小细胞肺癌(NSCLC)的免疫检查点抑制剂(ICI)治疗结局。模型在验证队列中预测客观缓解率(ORR)的AUC为0.66,模型评分是无进展生存和总生存的独立预测因子,且与PD-L1联合优于任一单独标志物。

要点

  • 深度学习模型预测ICI客观缓解率的AUC在内部测试集为0.75,在验证队列为0.66。
  • 验证队列中模型评分是无进展生存(HR 0.56)和总生存(HR 0.53)的独立预测因子。
  • 验证队列中模型联合PD-L1的AUC为0.70,优于任一单独标志物,缓解率51% vs PD-L1(≥50%)单用41%。

核心结论

  • 研究显示深度学习特征与NSCLC患者ICI反应独立相关,临床使用该模型可能细化治疗精准度并更好识别可能从ICI获益的晚期NSCLC患者。

研究设计与样本

  • 多中心队列研究,开发并独立验证基于全切片苏木精-伊红染色图像的深度学习反应分层模型,用于预测晚期NSCLC的ICI治疗结局。
  • 图像来自美国1个参与中心和欧盟3个参与中心,时间范围为2014年8月至2022年12月;数据分析时间为2022年9月至2024年5月。
  • 共纳入958例接受ICI治疗的NSCLC患者的295581个图像块,平均(SD)年龄66.0(10.6)岁,女性456例(48%)、男性502例(52%)。
  • 美国开发队列614例,中位(IQR)随访54.5(38.2-68.1)个月;欧盟验证队列344例,随访43.3(27.4-53.9)个月。
  • 暴露为ICI单药治疗。

主要发现

  • ICI的ORR在开发队列为26%,在验证队列为28%。
  • 深度学习模型预测ORR的AUC在内部测试集为0.75(95%CI 0.64-0.85),在验证队列为0.66(95%CI 0.60-0.72)。
  • 多变量分析中,验证队列深度学习模型评分是无进展生存(HR 0.56;95%CI 0.42-0.76;P<.001)和总生存(HR 0.53;95%CI 0.39-0.73;P<.001)的独立预测因子。
  • 调优后的深度学习模型在内部集中AUC高于TMB、TILs和PD-L1;在验证队列中优于TILs、与PD-L1相当(AUC 0.67;95%CI 0.60-0.74),特异性提高10个百分点。
  • 验证队列中深度学习模型联合PD-L1评分的AUC为0.70(95%CI 0.63-0.76),优于任一单独标志物,缓解率为51% vs PD-L1(≥50%)单用41%。

关键数值与推荐

  • 深度学习模型预测ORR的AUC:内部测试集0.75(95%CI 0.64-0.85),验证队列0.66(95%CI 0.60-0.72)。
  • 验证队列多变量分析:无进展生存HR 0.56(95%CI 0.42-0.76;P<.001),总生存HR 0.53(95%CI 0.39-0.73;P<.001)。
  • 验证队列中深度学习模型AUC 0.67(95%CI 0.60-0.74),与PD-L1相当,特异性提高10个百分点;联合PD-L1评分AUC 0.70(95%CI 0.63-0.76)。
  • 验证队列缓解率:深度学习模型联合PD-L1为51% vs PD-L1(≥50%)单用41%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Only a small fraction of patients with advanced non-small cell lung cancer (NSCLC) respond to immune checkpoint inhibitor (ICI) treatment. For optimal personalized NSCLC care, it is imperative to identify patients who are most likely to benefit from immunotherapy. OBJECTIVE: To develop a supervised deep learning-based ICI response prediction method; evaluate its performance alongside other known predictive biomarkers; and assess its association with clinical outcomes in patients with advanced NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study developed and independently validated a deep learning-based response stratification model for predicting ICI treatment outcome in patients with advanced NSCLC from whole slide hematoxylin and eosin-stained images. Images for model development and validation were obtained from 1 participating center in the US and 3 in the European Union (EU) from August 2014 to December 2022. Data analyses were performed from September 2022 to May 2024. EXPOSURE: Monotherapy with ICIs. MAIN OUTCOMES AND MEASURES: Model performance measured by clinical end points and objective response rate (ORR) differentiation power vs other predictive biomarkers, ie, programmed death-ligand 1 (PD-L1), tumor mutational burden (TMB), and tumor-infiltrating lymphocytes (TILs). RESULTS: A total of 295 581 image tiles from 958 patients (mean [SD] age, 66.0 [10.6] years; 456 [48%] females and 502 [52%] males) treated with ICI for NSCLC were included in the analysis. The US-based development cohort consisted of 614 patients with median (IQR) follow-up time of 54.5 (38.2-68.1) months, and the EU-based validation cohort, 344 patients with 43.3 (27.4-53.9) months of follow-up. The ORR to ICI was 26% in the developmental cohort and 28% in the validation cohort. The deep learning model's area under the receiver operating characteristic curve (AUC) for ORR was 0.75 (95% CI, 0.64-0.85) in the internal test set and 0.66 (95% CI, 0.60-0.72) in the validation cohort. In a multivariable analysis, the deep learning model's score was an independent predictor of ICI response in the validation cohort for both progression-free (hazard ratio, 0.56; 95% CI, 0.42-0.76; P < .001) and overall survival (hazard ratio, 0.53; 95% CI, 0.39-0.73; P < .001). The tuned deep learning model achieved a higher AUC than TMB, TILs, and PD-L1 in the internal set; in the validation cohort, it was superior to TILs and comparable with PD-L1 (AUC, 0.67; 95% CI, 0.60-0.74), with a 10-percentage point improvement in specificity. In the validation cohort, combining the deep learning model with PD-L1 scores achieved an AUC of 0.70 (95% CI, 0.63-0.76), outperforming either marker alone, with a response rate of 51% compared to 41% for PD-L1 (≥50%) alone. CONCLUSIONS AND RELEVANCE: The findings of this cohort study demonstrate a strong and independent deep learning-based feature associated with ICI response in patients with NSCLC across various cohorts. Clinical use of this deep learning model could refine treatment precision and better identify patients who are likely to benefit from ICI for treatment of advanced NSCLC.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Rakaee M, Tafavvoghi M, Ricciuti B, et al. Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2025. PMID: 39724105. doi:10.1001/jamaoncol.2024.5356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。